Emerging data suggest Retatrutide , a dual agonist targeting both GLP-1 and another hormone, may provide a notable development for obesity management . Preliminary patient trials have indicated https://freebookmarkpost.com/story21278257/the-retatru-tide-compound-a-breakthrough-in-body-management